Larvol Delta - Black-Diamond-Therapeutics-Announces-Positive-Phase-2-Results-for-Silevertinib-in-Frontline-NSCLC-Patients-with-EGFR-NonClassical-Mutations

silevertinib (BDTX-1535) - Black Diamond Therap

https://www.globenewswire.com/news-release/2026/05/21/3299802/0/en/Black-Diamond-Therapeutics-Announces-Positive-Phase-2-Results-for-Silevertinib-in-Frontline-NSCLC-Patients-with-EGFR-Non-Classical-Mutations.html

May 22, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next